Market Monitor chemicals Poland 2018

マーケットモニター

  • ポーランド
  • 化学・薬品

19 7 2018

Payment behaviour in the Polish chemicals sector has been good over the past two years, and the number of non-payments and insolvencies has been low.

Poland chemicals 2018 pic1

  • According to the Polish Central Statistical Office, chemicals production grew 4.6% in 2017, with rubber and plastics production even increasing 9.5%. In 2018 further production growth is expected, although at a slower pace, supported by GDP expansion forecast of more than 4%.

  • Many players have strong market positions, domestically as well as in Central and Eastern Europe. This enables them to focus on innovations (more than 20% of the existing patents in Poland stem from the chemicals sector) or to expand into new market segments with mergers and acquisitions.

  • Chemicals businesses’ profit margins are expected to remain stable in 2018. Gearing in the Polish chemicals sector is average, and many companies use investment credits in order to finance their investment projects for innovations. Polish banks are generally willing to provide loans to the industry. The Polish benchmark interest rate has remained low at 1.5% since March 2015, and the subsequent low interest rates for credit has spurred chemicals businesses to use bank loans to finance their investments.

  • On average, payments in the Polish chemicals sector take 30 to 60 days, but can take 180 to 240 days for seasonal products (e.g. fertilizers). Payment behaviour has been good over the past two years, and the number of non-payments and insolvencies has been low. Given the solid performance of the chemicals sector, no major increase in business failures is expected in 2018. However, in early 2018 we noticed several payment delays in the fertilizer distributors segment.

  • Our underwriting stance remains generally open for the chemicals sector. However, we are restrictive on fuel wholesalers and smaller fuel station chains in the petrochemicals subsector due to a grey economy in fuel trade in the past, which has led to increased VAT and excise tax controls.

  • Our underwriting stance for the pharmaceuticals segment is neutral, with a more cautious approach concerning drug wholesalers, as the government heavily regulates the market. New regulations on the concentration of pharmacies (e.g. restrictions on pharmacy ownership) and drug distribution could influence performance and results of all market players.

 

関連ドキュメント

免責条項

本ウェブサイトの記載事項は、一般的な情報提供のみを目的とし、何らの目的においてもこれに依拠すべきではありません。規定条件については、実際の保険契約または該当の製品・サービス契約をご覧ください。本ウェブサイトの記載事項は、買主についてのまたは利用者の代理人としてのデューデリジェンスの実施義務を含め、アトラディウス側に何らの権利、義務または責任を生じさせるものではありません。アトラディウスが買主についてデューデリジェンスを実施する場合は、当社の保険引受をその目的とし、被保険者その他の利益を目的とするものではありません。さらに、アトラディウスおよびその関連会社、系列会社、子会社は、本ウェブサイトの掲載情報の利用によって生じた直接的、間接的、特異的、付随的、結果的損害について一切の責任を負いません。